Skip to main content

News & events

-

IBA expands its activities in Sub-Saharan Africa and signs contract with Sweden Ghana Medical Centre for an IntegraLab® PLUS in Accra, Ghana

New contract to provide broader access to diagnostics in emerging markets   Louvain-La-Neuve, Belgium, October 13, 2022 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of radiopharmaceutical production solutions, today announces a new contract with Sweden Ghana Medical Centre (SGMC) for an IntegraLab® PLUS in Accra, Ghana. SGMC is a leading private cancer care center focused on providing the highest quality cancer treatment in West Africa. The contract marks IBA’s increasing presence in the region with operations in 21 countries.   IntegraLab® PLUS is a fully integrated solution that combines equipment and services for establishing a radiopharmaceutical GMP production center, tailored to each customer’s specific needs. The contract includes the delivery of an IntegraLab® solution, consisting of the installation and integration of a Cyclone® KIUBE 100 with Synthera® Extension, Synthera®+ HPLC and IFP loader. Sweden Ghana Medical Center will benefit from IBA's expertise for the complete setting-up of its radiopharmacy.   This contract follows several others signed in Tanzania and South Africa, and further highlights IBA’s ambition to broaden access to cancer diagnostics and treatments in regions of the world with low population density and limited access to healthcare. The demand for diagnostic and therapeutic equipment in Africa is rapidly growing, with cancer cases rising to over 800 000 cases* per year in Sub-Saharan Africa.   This latest announcement follows IBA’s launch of the Cyclone® KEY in January this year, which will provide more widespread global access to diagnostic solutions in oncology, neurology and cardiology as it answers a demand from the African market for a compact radiopharmaceuticals production solution.   Olivier Legrain, Chief Executive Officer at IBA, commented: “This contract marks an important milestone for IBA as we expand the use of our technology into emerging markets such as Africa. Continued innovation from our RadioPharma Solutions Business Unit is vital to providing patients with access to much needed diagnostics and treatments, something that is core to IBA’s mission and reinforced by the continued development of our technology. We look forward to working with SGMC and to helping them to achieve their mission of being at the forefront of cancer care in Africa.”   Dr. Clement Edusa, CEO and Medical Director at Sweden Ghana Medical Centre, added: “At SGMC, our vision is to provide the best possible cancer care across West Africa. The IntegraLab® will allow us to provide the most innovative diagnostic imaging tests to our patients, with the hope that we can identify disease and therefore start an appropriate course of treatment much quicker. IBA’s technology, not only provides us with a cost efficient and user-friendly cyclotron system but also tailored solutions that meet our specific needs, allowing us to provide the best possible care to our patients.”   *https://gco.iarc.fr/today/data/factsheets/populations/971-sub-saharan-africa-hub-fact-sheets.pdf
See more
IBA Press Release

ElsMed, Novatec and IBA sign contract to install radiopharmaceutical production center in Georgia

The center will be equipped with a Cyclone® KIUBE offering the highest production capacity with a PET cyclotron. Louvain-La-Neuve, Belgium, October 4, 2022 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of radiopharmaceutical production solutions, Novatec International and ElsMed Healthcare Solutions, the leading Israeli medical-technological company, announced today that they have signed a contract for the installation of an integrated radiopharmaceutical production facility in Tbilisi, Georgia. The project will be the first of its kind in Georgia and includes the construction of an ultra-modern radiopharmaceutical facility equipped with the latest technologies such as the IBA’s Cyclone® KIUBE and Synthera®+ platform. The center will produce various types of radiopharmaceutical products and is expected to start operations in 2024. The design, construction, operation, and production processes of the facility will be developed in line with the International Atomic Energy Agency (IAEA) standards and recommendations from IBA, as well as meeting set requirements defined by the legislation of Georgia. The General Director of Novatec International, Giorgi Glonti, commented: “This unique project for an on-site production facility for radiopharmaceutical compounds will significantly boost the development of nuclear medicine in the country of Georgia. This initiative will also contribute to increasing the availability of Positron-Emission Computed Tomography (PET-CT) for a wider population. The facility will be able to fully cover the current and future demand of the Georgian market, both in terms of production and delivery of fluorodeoxyglucose (18F-FDG) as well as other artificial radioactive isotopes.”   “Nowadays, radiopharmacies need to produce an increasing amount of FDG in a limited time frame, in addition to producing numerous other compounds. The Cyclone® KIUBE is the perfect solution providing the ability to produce the widest range of radioisotopes and covers all the needs of PET radiopharmacies,” said Bruno Scutnaire, President of IBA RadioPharma Solutions.   Hen Lederman, General Manager of the ElsMed Healthcare Solutions added: “We are pleased to participate in a such unique and useful project. Our joint efforts will have a significantly positive effect in the fight against cancer in Georgia, with ElsMed being additionally involved in the facility design and training of necessary personnel, in cooperation with leading nuclear medicine centers in Israel, and will provide continuous support until project completion.”
See more
IBA et SCK CEN lancent Pantera

IBA and SCK CEN launch Pantera, a joint-venture to produce actinium-225

Louvain-La-Neuve, Belgium, 22 September 2022 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, and the Belgian Nuclear Research Centre SCK CEN today announced the name of their joint-venture: Pantera SA/NV, which they believe will bring new hope for cancer patients. As indicated in the announcement of the R&D strategic partnership, this new company will aim to secure the large-scale production of actinium-225 (225Ac), one of the most promising alpha-emitting radioisotopes to fight cancers. By working towards this large-scale production, Pantera’s ultimate goal is to improve the accessibility of a future innovative cancer therapy based on 225Ac.   The complementarity of IBA and SCK CEN’s expertise has been demonstrated by the extensive and comprehensive R&D work that has been conducted during the last year as they work towards being able to produce large volumes of 225Ac. Pantera is now completing the technical feasibility studies before working on the final design and construction of its first facility in Mol, Belgium. Groundbreaking is expected to take place in 2024, with production starting in 2027.   Sven Van den Berghe, former Director of the Nuclear Materials Science Institute at SCK CEN, has been appointed as Chief Executive Officer, and Samy Bertrand, former technical leader for theranostics applications at IBA, takes the position of Chief Technical Officer.   Bruno Scutnaire, President of IBA RadioPharma Solutions and Chairman of the Board of Directors of Pantera, said: “Actinium-225 offers great promise for the treatment of a large variety of cancers, but only very little of the material is available worldwide today.  Once cancer treatments based on 225Ac receive approval, Pantera will focus on enabling access to a dependable supply of this promising isotope.”   Peter Baeten, Deputy Director-General of SCK CEN and Board member of Pantera, commented: “Launching Pantera was a logical choice for SCK CEN and IBA, allowing the joint-venture to leverage the innovative capabilities of both organizations, whilst utilizing the speed of an autonomous startup necessary in this fast-evolving field.”   Sven Van den Berghe, appointed Chief Executive Officer of Pantera, added: “I am excited about the opportunity to help advance the mission of Pantera to bring a new hope for cancer patients by enabling the widespread use of radioisotopes, such as actinium-225, as a basis for promising new radiopharmaceuticals. Pantera offers ’A better fight for life’, potentially bringing an effective and efficient treatment option while maximizing the quality of life of the patients, with the possibility to expand the production to other isotopes in the future.”   Actinium-225 possesses the resounding potential to treat cancers more effectively. Initial results show that the theranostic radioisotope completely eliminates cancer cells, rather than just inhibiting tumour growth. The risk of recurrence also appears to decrease. To date, extensive research and numerous studies are underway which aim to tackle both high prevalence cancers including prostate, lung, colon, breast, pancreatic, blood (leukemia and other rare forms) and kidney cancers, but also rarer forms of cancer like glioblastoma, the deadliest form of a very invasive brain cancer.  
See more

About us

Based on 35 years of experience, IBA RadioPharma Solutions helps nuclear medicine department to design, build and operate PET centers for the production of radiopharmaceuticals used for the detection and treatment of cancer and other critical diseases.

IBA works with you and supports you right through the whole process, from our first meeting through design, setting-up and operation. More than that, your IBA expert will support you throughout the lifetime of your radiopharmacy with trainings, updates and maintenances, to ensure the success of your project, for a sustainable future.

Read more
Who we are

Key facts

<strong>30</strong> Ci (up to)

Per production run.

For FDG production.

<strong>3</strong> (up to)

In one hotcell.

Multi tracers. Multi runs.

<strong>800</strong> +

Synthera® radiosynthesis modules installed worldwide.

<strong>300</strong> +

Cyclotrons operating and supported on 5 continents.